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(SD = 35.95) with CVD vs. €769.33 (SD = 8.02) without CVD,
p = 0.000. Patients with CVD showed better DBP control (74.9
± 9.7 vs. 76.44 ± 10.5), total cholesterol (194.8 ± 40.9 vs. 209.2
± 39.7) and LDLc (123.2 ± 37.3 vs. 138.4 ± 35.6); p = 0.000.
CONCLUSIONS: CVD prevalence is not very remarkable in
absolute terms; nevertheless, the costs corresponding to these
patients, adjusted for morbidity are important, increasing with
age and cause high sanitary resources consumption in Spanish
primary care centres. To achieve therapeutic goals in secondary
prevention with respect to the general population might be
improved.
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OBJECTIVE: CVI remains one of the most common diseases in
Poland with 40% prevalence. Thirteen percent of the population
with CVI receive some kind of treatment. The objective of this
analysis is to demonstrate the current cost of CVI in Poland.
METHODS: Study data were collected in the representative
group of 1000 people. A total of 223 patients who were receiv-
ing treatment (previously or currently) were further questioned
using a special resource utilisation questionnaire. Direct costs
included oral and local drugs (topical drugs and compression
therapy), surgical and cosmetic interventions, diagnostic tests
and hospitalisations. Indirect costs were calculated using the
human capital approach and included the costs of social and
family help, sick leaves and early retirements due to CVI.
RESULTS: The average total cost per person per year from the
investigated group is €356.82 with average direct costs of
€66.09. The total burden of CVI in Poland in terms of direct
medical costs may reach €504,418,178 (19% of the total cost).
The distribution of total costs per person in the investigated
group is as follows: oral treatment 2%, local treatment 2%, com-
pression therapy 1%, all surgical interventions 4%, hospitalisa-
tions 10%, family and social help 58%, sick leaves 13%,
pensions 10%. CONCLUSION: CVI remains a signiﬁcant eco-
nomic burden for the Polish population with total annual costs
up to €2,723,354,431. The main cost driver in the group of
direct medical costs (which comprise 29% of the total cost) is
the cost of hospitalisation (53%) while the cost of oral medica-
tion is the least signiﬁcant (2%). An early diagnosis and subse-
quent proper treatment of CVI may lead to an optimal allocation
of expenditures and contribute to a signiﬁcant reduction of the
total costs of CVI in Poland.
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OBJECTIVES: There are no data regarding the relationship of
cardiovascular risk factors (CVRF) as deﬁned in the ASCOT
(Anglo-Scandinavian Cardiac Outcomes Trial) and non-hospital
costs in hypertensive patients (HP) in Spain. The objectives of
this study are to determine the relationship between CVRF and
non-hospital costs in the HP. METHODS: HP data registered
between 2004 and 2005 from Spanish primary care centres were
retrospectively studied. We analyzed CVRF as deﬁned in
ASCOT: left-ventricular hypertrophy, other speciﬁed abnormal-
ities on EKG, type 2 diabetes, peripheral arterial disease, previ-
ous stroke, male gender, age ≥ 55 years, microalbuminuria,
smoking, ratio of plasma total cholesterol to HDL-cholesterol≥6,
or premature family history of CHD, and the following costs:
pharmacy, outpatient visits, radiology, other complementary
tests, sanitary transport, specialist visits and total costs. Corre-
lation between CVRF number and costs were calculated
(Kruskal-Wallis non-parametric test), and costs were compared
between HT with CVRF ≥ 3 and CVRF < 3 (Wilcoxon non-
parametric test). RESULTS: A total of 3410 HP were included in
the analysis, 158 (5%) of them have no aditional CVRF; 874
(26%) have 1; 1063 (31%): 2; 746 (22%): 3; 365 (11%): 4; 155
(5%): 5 and 49 (1%): ≥6. A signiﬁcant relationship was
demostrated among total costs and CVRF number (p < 0.0001).
The HP with CVRF ≥ 3 showed a cost signiﬁcantly higher than
CVRF < 3: €1611 vs. €1855 (p < 0.0001). The relationship was
as follow (CVRF number-Cost): 0 CVRF-€1289, 1 CVRF-€1603,
2 CVRF-€1666, 3 CVRF-€1759, 4 CVRF-€1890, 5 CVRF-
€2074, ≥6 CVRF-€2368. CONCLUSIONS: Additional CVRF 
in the hipertensive patients, not only increase CV risk, but 
the non-hopital costs as well. The patient with CVRF ≥ 3 showed
a greater non-hopital cost that those with CVRF < 3. It is 
important to analyze if this greater cost contributes to a greater
effectiveness and to implement the treatements that have demon-
strated beneﬁts in terms of morbimortality for this population.
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OBJECTIVE: To assess direct medical costs of three monother-
apies for treatment of mild to moderate hypertension in patients
with type II diabetes. METHODS: After a run-in period of 2
weeks, eligible patients PAD≤(90 < 140) were enrolled to a ran-
domized, parallel group clinical ≥ 110; PAS study lasting 50
weeks. Patients were randomized to the following treatments:
delapril (D) 30 mg/die, ramipril (R) 2.5 mg/die, valsartan (V) 
80 mg/die. After 6 weeks of active treatment, uncontrolled
patients were switched to combination therapy, whilst controlled
patients were maintained on their initial therapy up to the end
of the study period. This economic analysis was run for
monotherapy-treated patients and in the perspective of the
Italian NHS. Direct medical costs (year 2006) were considered:
study drugs, concomitant therapies, hypoglycaemic drugs,
unscheduled tests and visits and drugs used to treat adverse
events. RESULTS: A total of 236 patients in monotherapy
resulted eligible for the economic analysis. At the end of the
treatment period no statistically signiﬁcant differences were
found among the 3 study groups on the primary efﬁcacy vari-
able (PAD), on the number of patients requiring combination
therapy and on secondary efﬁcacy parameters. Cost-minimisa-
tion analysis was performed with costs normalised at 1 year to
account for slightly different lengths of follow-up. Total average
cost per patient/year for D vs. R vs. V was respectively €521 vs.
€636 and €742. Average cost per patient/year, for study drugs
was respectively €172; €174; €314; for medical visits €95; €94;
€92, for laboratory tests €69; €69; €68, for hypoglicaemics €151;
€233; €214 and for concomitant drugs €33; €67; €54. CON-
CLUSION: This study demonstrates that delapril in mild-mod-
erate hypertension for type II diabetes patients, is equally
effective as ramipril and valsartan whilst allowing consistent
reductions of medical costs/year (−18% and −30% of total per
patient cost respectively).
